AstraZeneca launches $1 billion R&D hub in Boston’s Kendall Square
AstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor.
The Boston location underscores the company’s commitment to expanding its presence in the United States, coming after a recent wave of Chinese‑led deals in the sector.
In related news, the FDA granted priority review to BridgeBio’s oral therapy for children with achondroplasia, with a final approval decision expected by February 4, 2027.
Japan’s Shionogi announced a $2 billion acquisition of U.S. biotech IntraBio, the maker of a drug that addresses neurological symptoms associated with its target condition.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: AstraZeneca opens new Boston site”
read at STAT ↗
comments(0)
5-min edit window · permanent after that